Article
Oncology
Sara Ribeirinho-Soares, Diana Padua, Ana Luisa Amaral, Elvia Valentini, Daniela Azevedo, Cristiana Marques, Rita Barros, Filipa Macedo, Patricia Mesquita, Raquel Almeida
Summary: In stage II CRC patients, low MUC2 expression, in combination with high CDX2 expression, absence of SOX2 or MMR-proficiency, is associated with worse prognosis, while none of these biomarkers showed prognostic value overall. Patients with low MUC2 expression derived significant benefit from adjuvant chemotherapy.
Article
Biochemistry & Molecular Biology
Yue Chen, Meng-huan Wang, Jin-yi Wu, Jian-yun Zhu, Chun-feng Xie, Xiao-ting Li, Jie-shu Wu, Shan-shan Geng, Ya-dong Li, Hong-yu Han, Cai-yun Zhong
Summary: Cancer stem cells (CSCs) are crucial in cancer and can be targeted by the natural compound SFN through the regulation of delta Np63α expression and the activation of core CSCs gene transcription.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2022)
Article
Oncology
E. Jifu, Zhengchun Kane, Jie Yuan, Zhaoming Wang, Defeng Tong, Junjie Xing
Summary: This study reveals that ZNF516 functions as a tumor suppressor in colorectal cancer by inhibiting stem cell-like characteristics and tumor progression. Overexpression of ZNF516 inhibits cell proliferation, invasion, and the development of stem cell-like characteristics through regulating the transcription of Sox2.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Yan Fu, Chen Bai, Shengsheng Wang, Denggang Chen, Peng Zhang, Hailang Wei, Fan Rong, Chao Zhang, Shaojuan Chen, Zhenjun Wang
Summary: Colorectal cancer (CRC) is a major cause of cancer-related death, and the presence of cancer stem cells (CSC) contributes to tumor relapse and drug resistance. Targeting alternative splicing has shown promise in treating CRC. This study identified RBM17 as an oncogene in CRC cells, promoting CSC properties through the regulation of FOXM1 and Sox2 expression. AKT1 was also found to be an upstream kinase in the control of RBM17-mediated alternative splicing and enhancement of CSC properties in CRC cells. This study suggests that the AKT1-RBM17-FOXM1-Sox2 axis could be a potential target for modulating alternative splicing and reducing CSC properties in CRC.
Article
Medicine, Research & Experimental
Zhengguang Li, Zhirong Yang, Wei Liu, Wanglong Zhu, Lan Yin, Zhenyu Han, Yu Xian, Jie Wen, Hualong Tang, Xinyue Lin, Yuhan Yang, Jingyi Wang, Kun Zhang
Summary: The study revealed that DVL3 is overexpressed in colorectal cancer (CRC) and is associated with malignant behaviors, metastasis, and prognosis. Furthermore, DVL3 promotes epithelial-to-mesenchymal transition (EMT) and cancer stem-like cell (CSLC) properties in CRC through the activation of the Wnt/beta-catenin/c-Myc/SOX2 axis. This research provides a new strategy for successful treatment of CRC.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, General & Internal
Hong Bae Choi, Jung-Soo Pyo, Soomin Son, Kyungdoc Kim, Guhyun Kang
Summary: The study evaluates the diagnostic and prognostic role of CDX2 expression in colorectal cancers (CRCs) through a meta-analysis. The results show that CDX2 expression is associated with clinicopathological characteristics of CRC. CDX2 is highly expressed in adenocarcinoma and lowly expressed in medullary carcinoma. In addition, CDX2 expression is correlated with the presence of BRAF(V600E) mutation. Patients with CDX2 expression have better survival rates.
Article
Multidisciplinary Sciences
Matias Blomqvist, Ilmari Koskinen, Eliisa Loyttyniemi, Tuomas Mirtti, Peter J. Bostrom, Pekka Taimen
Summary: In bladder cancer patients, the stem cell markers ALDH1, SOX2, and SSEA-4 show little prognostic or predictive value, with weak or negative cytoplasmic SOX2 staining being associated with lymphovascular invasion and cancer-specific survival but not significantly.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Junhui Yu, Kui Yang, Jianbao Zheng, Pengwei Zhao, Jie Xia, Xuejun Sun, Wei Zhao
Summary: Our study reveals the regulatory mechanism of EZH2-mediated FXR silencing in colorectal tumorigenesis. We demonstrate that the combination of FXR agonist OCA and EZH2 inhibitor GSK126 exhibits synergistic inhibition effects on colon cancer cells by suppressing clonogenic growth, invasion, and promoting apoptosis. Mechanistically, the drug combination accelerates FXR nuclear location and upregulates CDX2 expression. Depletion of CDX2 attenuates the synergistic effects of the drug combination.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Jagdeep Singh, N. G. Rajesh, Biswajit Dubashi, Nanda Kishore Maroju, Prasanth Ganesan, Kiran Kumar Matta, I Charles, Smita Kayal
Summary: Loss of CDX2 expression is significantly associated with advanced stage, higher tumor grade, presence of lymphovascular invasion, and worse prognosis in colorectal cancer.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Cell Biology
Ji-Hye Park, Young-Heon Kim, Sehwan Shim, Areumnuri Kim, Hyosun Jang, Su-Jae Lee, Sunhoo Park, Songwon Seo, Won Il Jang, Seung Bum Lee, Min-Jung Kim
Summary: SOX2 plays a crucial role in maintaining colorectal cancer stem-like properties by regulating CD44 expression through the PI3K/AKT pathway, leading to enhanced resistance to radiation and metastatic potential. This highlights the potential of SOX2 as a therapeutic target in aggressive colorectal cancer.
Article
Biochemistry & Molecular Biology
Larischa de Wet, Anthony Williams, Marc Gillard, Steven Kregel, Sophia Lamperis, Lisa C. Gutgesell, Jordan E. Vellky, Ryan Brown, Kelly Conger, Gladell P. Paner, Heng Wang, Elizabeth E. Platz, Angelo M. De Marzo, Ping Mu, Jonathan L. Coloff, Russell Z. Szmulewitz, Donald J. Vander Griend
Summary: This study investigated the impact of SOX2 expression on patient outcomes and its function within prostate cancer cells. The results revealed that SOX2 expression promotes metastatic progression and therapy resistance in prostate cancer, and affects the metabolic pathways and metabolites of cancer cells. These findings contribute to a better understanding of the role of SOX2 in prostate cancer and suggest its potential as a biomarker and pharmacologic target in clinical settings.
Article
Biochemistry & Molecular Biology
Mariana Nunes, Francisca Pacheco, Ricardo Coelho, Dina Leitao, Sara Ricardo, Leonor David
Summary: Overexpression of MSLN in ovarian carcinomas does not affect the expression of cancer stem cell markers, indicating that MSLN is not involved in driving the cancer stem cell phenotype.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biotechnology & Applied Microbiology
Xin Zhao, Jincheng Wu, Yongwen Li, Feng Ye, Chunyue Wang
Summary: The study found that lncRNA FENDRR can block the CSC-like traits in colorectal cancer cells by directly interacting with Sox2 mRNA 3'UTR, with its overexpression attenuating these traits and its knockdown enhancing them.
Article
Environmental Sciences
Huaqiang You, Shan Gao, Xiaoping Xu, Hong Yuan
Summary: The study identified the promoting roles of FGD5 in gastric cancer progression through its interaction with Sox2 protein, which regulates CSC progression, supporting the CSC-like traits dependent on Sox2 expression.
ENVIRONMENTAL TOXICOLOGY
(2021)
Article
Nutrition & Dietetics
Tafirenyika Gwenzi, Petra Schrotz-King, Ben Schoettker, Michael Hoffmeister, Hermann Brenner
Summary: According to recent evidence, the prognostic value of Vitamin D (VitD) status for colorectal cancer (CRC) patients might be confined to patients with the GG genotype of Cdx2, a functional polymorphism of the VitD receptor gene. In this study, the researchers aimed to validate these findings in a cohort of CRC patients by measuring serum VitD concentration and performing Cdx2 genotyping. The results showed that VitD deficiency is associated with poorer survival, particularly in patients with the GG genotype of Cdx2.